Phase 4 Eczema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are adults (18 years of age or older)
- People who have been diagnosed with atopic eczema (a chronic skin condition that causes itching and inflammation)
- People who are currently receiving a medication called dupilumab at a dose of 300 mg every two weeks to treat their atopic eczema
- People whose eczema is considered well-controlled based on a specific set of medical measurements called the Treat-to-Target criteria
- People who are comfortable with the possibility that their dupilumab dose may be reduced as part of the trial
- People who have voluntarily signed and dated a consent form before any trial-related procedures take place
Who may not be able to join:
- People who are currently using, or plan to start using, another medication that affects the immune system (taken as a tablet, injection, or infusion rather than a cream) — whether for atopic eczema or for any other condition
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Louise AA Gerbens, MD PhD, Amsterdam UMC, location VUmc
Phone: +3120 566 9111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Mean EASI
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.